Monte Rosa Therapeutics
Update in progressGLUE (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Monte Rosa Therapeutics is a clinical‑stage biotechnology company that develops small‑molecule precision medicines using molecular glue degraders to selectively target disease‑driving proteins. Its programs include MRT‑2359 for MYC‑driven tumors, MRT‑6160 for neurologic and autoimmune diseases, MRT‑8102 for IL‑1–driven inflammation, and CDK2 cancer programs. It also advances QuEEN discovery, collaborates with Roche and Novartis, was founded in 2019, and is based in Boston.
Company score
- Sentiment
- 0.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!